iTolerance

iTolerance is an early-stage private regenerative medicine company that develops technologies to enable tissue, organoid, or cell therapy without the need for lifelong immunosuppression. iTOL-100 advances a pipeline of projects using allogeneic islets and disease-curing potential stem cells based on its proprietary biotechnology-derived Strepavidin-FasL fusion protein/biotin-peg microgel (SA-FasL microgel) platform technology.